Randomized trial demonstrates reduced cognitive and functional decline with lecanemab in early Alzheimer's disease, highlighting therapeutic potential despite adverse events.
Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455.).
No takes yet. Share an insight, caveat, or question.
Dyck et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: